Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Censoring Survival Data01:09

Censoring Survival Data

Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different reasons...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A joint model for longitudinal measurements and survival data in the presence of multiple failure types.

Biometrics·2007
Same author

Na+-dependent neutral amino acid transporter ASCT2 is downregulated in seriously traumatized human intestinal epithelial cells.

Journal of pediatric gastroenterology and nutrition·2007
Same author

The health effects of non-industrial indoor air pollution.

The Journal of allergy and clinical immunology·2007
Same author

Biodiversity of pig breeds from China and Europe estimated from pooled DNA samples: differences in microsatellite variation between two areas of domestication.

Genetics, selection, evolution : GSE·2007
Same author

Genome-wide analysis reveals regulatory role of G4 DNA in gene transcription.

Genome research·2007
Same author

Functional roles of a Ca2+-activated K+ channel in atrioventricular nodes.

Circulation research·2007
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Missing data handling methods in medical device clinical trials.

Xu Yan1, Shiowjen Lee, Ning Li

  • 1U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Journal of Biopharmaceutical Statistics
|February 26, 2010
PubMed
Summary
This summary is machine-generated.

Missing data in clinical trials can bias results. Tipping-point analysis helps assess the impact of missing data in medical device trials, aiding robust interpretation of treatment effects.

Related Experiment Videos

Last Updated: Jun 15, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Area of Science:

  • Clinical Trials Analysis
  • Biostatistics
  • Medical Device Research

Background:

  • Missing data due to patient dropout is a significant challenge in clinical trial analysis.
  • Unaccounted missing data can lead to biased treatment comparisons and affect study outcome interpretation.
  • Regulatory bodies often require sensitivity analyses to ensure the robustness of clinical trial findings.

Purpose of the Study:

  • To discuss methods for handling missing data specifically within medical device clinical trials.
  • To highlight tipping-point analysis as a key approach for evaluating the impact of missing data.
  • To provide a framework for assessing the plausibility of unfavorable outcomes due to missing data.

Main Methods:

  • Focus on tipping-point analysis as a general method for missing data assessment.
  • Define tipping points as outcomes that alter the study's conclusion.
  • Illustrate the application of these methods using three distinct examples with varying missing data rates.

Main Results:

  • Tipping-point analysis provides a quantifiable measure of missing data's potential impact.
  • The method assists clinical reviewers in judging the reliability of treatment effect estimates.
  • Demonstrates how to assess whether observed results remain valid under various missing data scenarios.

Conclusions:

  • Tipping-point analysis is a valuable tool for evaluating the robustness of medical device clinical trial results.
  • This approach enhances the interpretability of study findings when faced with missing data.
  • It supports regulatory decision-making by providing evidence on the sensitivity of conclusions to missing data.